FLOWER-MI Sub-Studies Coming Out Generate More Questions about FFR

The FLOWER-MI (presented simultaneously at ACC 2021 and NEJM) hit FFR hard. Its outcomes showed that STEMI patients presenting other non-culprit lesions did not benefit from FFR guided revascularization vs PCI.

FLOWER-MI que generan más preguntas sobre el FFR

As it happens with most large studies with unexpected results in the general population, the sub-studies that follow select better samples and, as a result, show different outcomes.

This study focused on the FLOWER-MI arm receiving FFR. It compared one-year outcomes of patients with preserved FFR managed conservatively vs. patients with low FFR undergoing PCI

Primary end point was a combination of all cause death non-fatal infarction and emergency revascularization at one year. 

Of 1,171 patients included in the original study 586 were assessed with FFR. 66% of these patients presented at least one lesion requiring PCI and the remaining 34% showed preserved FFR in all non-culprit lesions and was managed conservatively.

Mean FFR before decision of non-culprit lesions were 0.75±0.10 and 0.88±0.06, respectively.


Read also: ESC 2021 | Acute and Chronic Myocardial Injury in COVID-19 Patients and Impact in Mortality.


After a year followup there was a 4.1% events rate in patients undergoing PCI vs nearly a twice as higher rate among patients managed conservatively (8.1%). This difference resulted significative (p=0.02).

Do these results clarify our vision of FFR or do they make it even more blurry? Patients who did not receive PCI because of preserved FFR presented twice as many events. There is plenty of evidence on the safety of deferring lesions using FFR, but this study appears to be an exception. 

We could speculate (understanding the value of FFR as a continuum) that deferred patients had values close to the cutoff value.


Read also: ESC 2021 | STEP: Blood Pressure Values in the Elderly, A Never-Ending Debate.


However, this is not the case in this study. Deferred patients had mean FFR 0.88, far from 0.8, putting us at ease. 

All in all, there will be more studies following the FLOWER-MI for us to be able to define how to proceed with MI non-culprit lesions. 

Conclusion

Patients undergoing ST elevation MI presenting other non-culprit lesions benefit from FFR guided complete revascularization only when receiving PCI to at least one lesion. 

Patients with preserved FFR to all non-culprit lesions (and therefore deferred) saw significantly more events at one year. 

Original Title: Compared Outcomes of ST-Elevation Myocardial Infarction Patients with Multivessel Disease Treated with Primary Percutaneous Coronary Intervention and Preserved Fractional Flow Reserve of Non-Culprit Lesions Treated Conservatively and of Those with Low Fractional Flow Reserve Managed Invasively: Insights from the FLOWER MI Trial.

Reference: Pierre Denormandie et al. Circ Cardiovasc Interv. 2021 Aug 23. Online ahead of print. doi: 10.1161/CIRCINTERVENTIONS.121.011314. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...